Stephanie A Freeman1, Susan C Modesitt. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Chandler Medical Center, Lexington, KY 40536-0298, USA.
Abstract
BACKGROUND: Ovarian sex cord stromal tumors are frequently hormonally active, and adult granulosa cell tumors often demonstrate estrogen receptor positivity. Thus, hormonal agents have been evaluated as potential treatments for advanced stage or recurrent adult granulosa cell tumors. CASE: Two cases of patients with recurrent adult granulosa cell tumors are presented. Each patient received multiple treatment modalities including chemotherapy and had previously progressed on leuprolide. Both patients were started on anastrozole with subsequent normalization of inhibin B levels and clinical exams. They have been maintained on treatment for 14 and 18 months, respectively, and have tolerated the drug without difficulty. CONCLUSION: Aromatase inhibitors may be a viable treatment option for women with advanced stage or recurrent ovarian adult granulosa cell tumors.
BACKGROUND:Ovarian sex cord stromal tumors are frequently hormonally active, and adult granulosa cell tumors often demonstrate estrogen receptor positivity. Thus, hormonal agents have been evaluated as potential treatments for advanced stage or recurrent adult granulosa cell tumors. CASE: Two cases of patients with recurrent adult granulosa cell tumors are presented. Each patient received multiple treatment modalities including chemotherapy and had previously progressed on leuprolide. Both patients were started on anastrozole with subsequent normalization of inhibin B levels and clinical exams. They have been maintained on treatment for 14 and 18 months, respectively, and have tolerated the drug without difficulty. CONCLUSION: Aromatase inhibitors may be a viable treatment option for women with advanced stage or recurrent ovarian adult granulosa cell tumors.
Authors: David Fu; Xiangmin Lv; Guohua Hua; Chunbo He; Jixin Dong; Subodh M Lele; David Wan-Cheng Li; Qiongli Zhai; John S Davis; Cheng Wang Journal: Endocr Relat Cancer Date: 2014-03-04 Impact factor: 5.678
Authors: E Kempf; G Desamericq; B Vieites; I Diaz-Padilla; E Calvo; P Estevez; A Garcia-Arreza; M A Martinez-Maestre; I Duran Journal: Clin Transl Oncol Date: 2016-05-18 Impact factor: 3.405
Authors: Hyun Jung Kim; Sang-Cheol Lee; Sang Byung Bae; Kye Won Kwon; Chan Kyu Kim; Nam Su Lee; Kyu Taek Lee; Jong Ho Won; Dae Sik Hong; Hee Sook Park Journal: J Korean Med Sci Date: 2009-06-18 Impact factor: 2.153
Authors: Kamila A Solak; Fiona M J Wijnolts; Sandra M Nijmeijer; Bas J Blaauboer; Martin van den Berg; Majorie B M van Duursen Journal: Toxicol Rep Date: 2014-07-07
Authors: Asaf Maoz; Koji Matsuo; Marcia A Ciccone; Shinya Matsuzaki; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson Journal: Cancers (Basel) Date: 2020-05-29 Impact factor: 6.639